Biopharmaceutical company GSK plc (LSE/NYSE:GSK) confirmed on Tuesday that it is appealing a Delaware court decision allowing plaintiff expert testimony in the ongoing Zantac (ranitidine) litigation.
The company argues that the ruling contradicts how the Daubert standard is typically applied and could impact all Delaware businesses.
GSK, joined by Pfizer (NYSE:PFE), Sanofi (Euronext Paris:SAN) (Nasdaq:SNY) and Boehringer Ingelheim, has filed with the Delaware Supreme Court seeking to overturn the lower court's decision. GSK maintains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
A decision on whether to grant interlocutory review and hear the appeal is expected later this year.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen